Azilsartan
 | |
| Systematic (IUPAC) name | |
|---|---|
|
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-([2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl)-1H-benzimidazole-7-carboxylate | |
| Clinical data | |
| Trade names | Edarbi |
| AHFS/Drugs.com | Consumer Drug Information |
| MedlinePlus | a611028 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Oral |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number |
147403-03-0  |
| ATC code | C09CA09 (WHO) |
| PubChem | CID 9825285 |
| IUPHAR/BPS | 6900 |
| ChemSpider |
9413866  |
| UNII |
F9NUX55P23 |
| ChEBI |
CHEBI:68845 |
| ChEMBL |
CHEMBL57242 |
| Synonyms | Azilsartan medoxomil |
| Chemical data | |
| Formula | C25H20N4O5 |
| Molar mass | 456.46 g/mol |
| |
| |
| (what is this?) (verify) | |
Azilsartan (INN, codenamed TAK-536) is an angiotensin II receptor antagonist used in the treatment of hypertension, developed by Takeda.
It is marketed in tablet form under the trade name Edarbi as the prodrug azilsartan medoxomil (INN, codenamed TAK-491). On 25 February 2011, the U.S. Food and Drug Administration approved azilsartan medoxomil for the treatment of high blood pressure in adults.[1] On March 8, 2012, Health Canada approved the drug for mild to moderate essential hypertension. [2]
Contraindications
Azilsartan should not be used with aliskiren, a renin inhibitor, in patients with diabetes as this increases the risk of serious adverse effects.
Mechanism of action
Main article: Angiotensin II receptor antagonist
Azilsartan medoxomil lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone.
Azilsartan medoxomil, the prodrug used, Edarbi
References
- ↑ "FDA approves Edarbi to treat high blood pressure" (Press release). U.S. Food and Drug Administration. February 25, 2011. Retrieved 2011-03-01.
- ↑ Notice of Decision for EDARBI
| ||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Monday, April 11, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.